This technology provides a pharmaceutical composition for anti-aging containing the circulating aging marker microRNA-21a-5p, which decreases in blood expression with age, as an active ingredient, and a method for inducing anti-aging in animals by administering it.
Existing aging research has focused on analyzing indicators of age-related diseases such as diabetes, hypertension, and dementia, as well as delaying aging, leaving a lack of approaches to reverse the aging state itself. Furthermore, protein-based aging diagnostics have limitations, as they are unstable in environments with varying temperatures and pH levels, making it difficult to obtain consistent results.
This technology identifies blood microRNAs that consistently decrease with age and supplies them to the body to regulate the expression of aging-related genes in specific organs, such as the liver, thereby going beyond delaying aging to inducing anti-aging. It can be used in combination with other aging markers such as microRNA-16-5p and microRNA-17-5p. Applicable to the development of treatments for age-related diseases, pet aging management products, and anti-aging drugs, it presents a new therapeutic strategy that fundamentally regulates aging genes.
This invention was developed with support from the Ministry of Science, ICT and Future Planning for research on the mechanisms of animal cell aging.
N/A
